FLGT - Fulgent Genetics, Inc.
After hours:
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 40.70 |
| Open | 41.06 |
| Bid | 40.27 x 1000 |
| Ask | 41.84 x 800 |
| Day's Range | 39.81 - 41.58 |
| 52 Week Range | 28.27 - 65.17 |
| Volume | |
| Avg. Volume | 236,055 |
| Market Cap | 1.198B |
| Beta (5Y Monthly) | 1.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.88 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.33 |
Fair Value
Related Research
Motley FoolBetter Diversified Biotech Stock: 23andMe vs. Fulgent Genetics
Most biotechs don't have a diversified business model. Both 23andMe and Fulgent provide genetic testing and diagnostic services as well as perform drug development. The idea is that there's probably a competitive advantage of some kind in drug development, lurking somewhere in the reams of genetic information that the companies generate via their testing services.
Motley Fool2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years
One of the best investment strategies is to buy shares of companies that are presently beaten down by the market, but in whose businesses you have full confidence for growth over the long term. Then, as the market bids up their valuation over time, you'll get the benefit of both the company's actual growth as well as its strengthening reputation among other investors. Two stocks the market is ignoring today, but could likely become excellent investments in the next decade, are in the biotechnology space.
Business WireFulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting
EL MONTE, Calif., May 18, 2023--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that Phase 1/1b clinical data on its lead therapeutic development candidate, FID-007, to treat various solid tumors, will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting at 8:00 a.m. Central Time on June 3, 2023 in Chicago, Illinoi
TheStreet.com3 Cash-Rich Biotechs in a Market That's Tough on the Debt Burdened
There are reasons besides their cash positions to think these companies could see their stocks improve going forward.
ZacksIs Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?
Here is how Fulgent Genetics, Inc. (FLGT) and Masimo (MASI) have performed compared to their sector so far this year.
ZacksFulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 51.11% and 6.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireFulgent Reports First Quarter 2023 Financial Results
EL MONTE, Calif., May 05, 2023--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2023.
Business WireFulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023
TEMPLE CITY, Calif., April 20, 2023--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its first quarter 2023 financial results before the market opens on Friday, May 5, 2023. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questio
InvestorPlace7 Stocks to Buy to Bag Big-Time Returns in Q2
If you’re the type that runs toward danger, these stocks to buy may be right for you. To facilitate mobility, the enterprises on this list feature a market capitalization between $500 million to $2 billion. With this list, I searched for stocks to buy that benefit from upside analyst targets. In addition, it’s worth pointing out before anyone gets any weird ideas: all of these opportunities should be considered speculative. Yes, you can make money, but you can just as easily lose it. In other wo
Simply Wall St.Returns Are Gaining Momentum At Fulgent Genetics (NASDAQ:FLGT)
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
ZacksStrength Seen in Nyxoah SA (NYXH): Can Its 10.2% Jump Turn into More Strength?
Nyxoah SA (NYXH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ZacksAre Medical Stocks Lagging Fulgent Genetics (FLGT) This Year?
Here is how Fulgent Genetics, Inc. (FLGT) and Harrow Health (HROW) have performed compared to their sector so far this year.
PR NewswireMission Bio Partners with Fulgent Genetics to Broaden Accessibility of Single-Cell Multi-Omics for Drug Development and Clinical Research
Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced that it has entered into an agreement with Fulgent Genetics (NASDAQ: FLGT), a technology-based company with well-established clinical diagnostic and therapeutic development businesses. Fulgent Genetics is now able to offer single-cell multi-omics on the Tapestri Platform on its fully customizable menu of services, including whole genome, whole exome, RNA sequencing, tumor profiling, methyl
- Simply Wall St.
Fulgent Genetics (NASDAQ:FLGT) shareholders are still up 654% over 5 years despite pulling back 7.1% in the past week
Buying shares in the best businesses can build meaningful wealth for you and your family. And we've seen some truly...
ZacksIs Fulgent Genetics (FLGT) Outperforming Other Medical Stocks This Year?
Here is how Fulgent Genetics, Inc. (FLGT) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
- Simply Wall St.
Earnings Beat: Fulgent Genetics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
It's been a good week for Fulgent Genetics, Inc. ( NASDAQ:FLGT ) shareholders, because the company has just released...
Insider MonkeyFulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2022 Earnings Call Transcript
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Hello and welcome to the Fulgent Genetics Q4 and Fiscal Year 2022 Earnings Conference Call and Webcast. As a reminder, this conference is being recorded. It’s now my pleasure to turn the call over to Melanie Solomon, Investor Relations. Please go ahead. […]
- Thomson Reuters StreetEvents
Q4 2022 Fulgent Genetics Inc Earnings Call
Q4 2022 Fulgent Genetics Inc Earnings Call
ZacksFulgent Genetics, Inc. (FLGT) Reports Q4 Loss, Tops Revenue Estimates
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 14.29% and 13.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireFulgent Reports Fourth Quarter and Full Year 2022 Financial Results
TEMPLE CITY, Calif., February 28, 2023--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent", or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2022.
Business WireFulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel
TEMPLE CITY, Calif., February 28, 2023--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced the immediate availability of their new Beacon787 expanded carrier screening panel. Beacon787 will include a total of 787 genes associated with autosomal recessive and X-linked conditions. Included in this panel are all of the American College of Medical G
TheStreet.comThis Medical Play Is Up to the Test
Fulgent Genetics saw explosive sales growth in 2021, thanks to its Covid 19 testing portfolio, which is rapidly ramping down as the pandemic is finally ebbing. At the height of the pandemic, Covid testing was providing over $200 million in sales a quarter. Fulgent Genetics has an approximate market capitalization of $950 million at current trading levels.
Business WireFulgent to Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference
TEMPLE CITY, Calif., February 23, 2023--Fulgent, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that members of its management team are scheduled to participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference on Tuesday, March 7, 2023.
Business WireFulgent Genetics to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
TEMPLE CITY, Calif., February 14, 2023--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology, today announced that it will release its fourth quarter and full year 2022 financial results after the market closes on Tuesday, February 28, 2023. Management will host a conference call for the investment community
- Simply Wall St.
Is Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Latest Stock Performance A Reflection Of Its Financial Health?
Most readers would already be aware that Fulgent Genetics' (NASDAQ:FLGT) stock increased significantly by 17% over the...